A European Multicenter Randomized Double-blind Placebo-controlled Monotherapy Clinical Trial of Milnacipran in Treatment of Fibromyalgia

This randomized, double-blind, placebo-controlled, multicenter study investigated the efficacy and safety of milnacipran in the treatment of fibromyalgia (FM) in a European population. Outpatients diagnosed with FM according to 1990 American College of Rheumatology criteria (N = 884) were randomized...

Full description

Saved in:
Bibliographic Details
Published in:Journal of rheumatology 2010-04, Vol.37 (4), p.851-859
Main Authors: BRANCO, Jaime C, ZACHRISSON, Olof, PERROT, Serge, MAINGUY, Yves
Format: Article
Language:English
Subjects:
Adult
Aged
Biological and medical sciences
Cyclopropanes - therapeutic use
Diseases of the osteoarticular system
Double-Blind Method
Drug Administration Schedule
Female
Fibromyalgia - drug therapy
Humans
Male
Medical sciences
Middle Aged
Miscellaneous. Osteoarticular involvement in other diseases
Pain - drug therapy
Pain Measurement
Patient Satisfaction
Serotonin Uptake Inhibitors - therapeutic use
Severity of Illness Index
Surveys and Questionnaires
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This randomized, double-blind, placebo-controlled, multicenter study investigated the efficacy and safety of milnacipran in the treatment of fibromyalgia (FM) in a European population. Outpatients diagnosed with FM according to 1990 American College of Rheumatology criteria (N = 884) were randomized to placebo (n = 449) or milnacipran 200 mg/day (n = 435) for 17 weeks (4-week dose escalation, 12-week stable dose, 9-day down-titration), followed by a 2-week posttreatment period. The primary efficacy criterion was a 2-measure composite responder analysis requiring patients to achieve simultaneous improvements in pain (>or= 30% improvement from baseline in visual analog scale, 24-hour morning recall) and a rating of "very much" or "much" improved on the Patient Global Impression of Change scale. If responder analysis was positive, Fibromyalgia Impact Questionnaire (FIQ) was included as an additional key primary efficacy measure. At the end of the stable dose period (Week 16), milnacipran 200 mg/day showed significant improvements from baseline relative to placebo in the 2-measure composite responder criteria (p = 0.0003) and FIQ total score (p = 0.015). Significant improvements were also observed in multiple secondary efficacy endpoints, including Short-Form 36 Health Survey (SF-36) Physical Component Summary (p = 0.025), SF-36 Mental Component Summary (p = 0.007), Multidimensional Fatigue Inventory (p = 0.006), and Multiple Ability Self-Report Questionnaire (p = 0.041). Milnacipran was safe and well tolerated; nausea, hyperhidrosis, and headache were the most common adverse events. Milnacipran is an effective and safe treatment for pain and other predominant symptoms of FM. Registered as trial no. NCT00436033.
ISSN:0315-162X
1499-2752
DOI:10.3899/jrheum.090884